Optimization of gastroesophageal reflux disease treatment with concomitant obesity: new approaches and perspectives.

Abstract

In recent decades, there has been a rapid increase in obesity among the working-age population. Excess weight is associated with an elevated risk of developing gastrointestinal pathology, including gastroesophageal reflux disease (GERD). The aim of this study was to investigate the effectiveness and rationale for the addition of tyrosine-2-alanylglycyl-phenylalanyl-leucyl-arginine diacetate (dalarin) to the standard GERD treatment regimen. Materials and Methods: A total of 110 study participants were divided into two groups: 40 patients with GERD without concomitant obesity and 70 patients with GERD and grade I obesity. One group received the standard treatment protocol, while the other group received dalarin as an additional medication. Disease progression was assessed after a three-week period using clinical, laboratory, and instrumental examinations. Results: The results of clinical, laboratory, and instrumental examinations provide evidence that combined treatment with the inclusion of dalarin surpasses the effectiveness of the standard treatment protocol in both the isolated GERD group and the GERD group with concomitant obesity.